logo-loader
viewLexagene Holdings Inc

LexaGene moves forward with its faster, easier pathogen detection

LexaGene Holdings (CVE:LXG) (OTCQB:LXXGF) Co-founder and CEO Dr. Jack Regan joined Katie Lewis from the Vancouver studio of Proactive Investors to discuss the firm's recent announcement.

LexaGene's key feature is the open access nature of the instrument that allows end users to customize the instrument to target any pathogen of interest. The process is as simple as collecting a sample, loading it into the instrument using a preparation cartridge and pressing “go.” The instrument is able to process multiple samples at a time, returning results within around one hour.forward with its faster, easier pathogen detection

Quick facts: Lexagene Holdings Inc

Price: 0.5 CAD

TSX-V:LXG
Market: TSX-V
Market Cap: $42.83 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Lexagene Holdings Inc named herein, including the promotion by the Company of Lexagene Holdings Inc in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Lexagene Develops technology to test for deadly mosquito...

Lexagene (CVE: LXG-OTCQB-LXXGF) Founder and CEO Dr jack Regan joined Steve Darling from Proactive Vancouver on Skype with news the company has used their proprietary technology to develop a detection system for the Eastern Equine Encephalitis or EEE. Regan says that not only can they use the...

on 17/9/19

2 min read